United Therapeutics (UTHR) EBITDA Margin (2009 - 2026)

United Therapeutics has disclosed EBITDA Margin across 18 years of filings, most recently posting 42.23% for Q2 2026.

• In Q2 2026, EBITDA Margin fell 341.0% year-over-year to 42.23%; the TTM figure through Jun 2026 stood at 44.44% (down 261.0% YoY), while the FY2025 annual figure was 46.89%, down 96.0% from the prior year.
• EBITDA Margin came in at 42.23% for Q2 2026 at United Therapeutics, up from 41.69% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 62.35% in Q1 2022 to a low of 35.73% in Q4 2022.
• Average EBITDA Margin over 5 years is 48.34%, with a median of 47.0% recorded in 2024.
• Year-over-year, EBITDA Margin soared 7944 bps in 2022 and plunged 785 bps in 2024.
• Over 5 years, EBITDA Margin stood at 35.73% in 2022, then grew by 18 bps to 42.31% in 2023, then increased by 15 bps to 48.61% in 2024, then fell by 7 bps to 45.14% in 2025, then retreated by 6 bps to 42.23% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 42.23% in Q2 2026, 41.69% in Q1 2026, and 45.14% in Q4 2025.